Rhythm Pharmaceuticals, Inc.
RYTM
$115.48
-$0.54-0.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 18.54% | 4.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 18.54% | 4.99% | |||
| Cost of Revenue | 24.79% | 49.04% | |||
| Gross Profit | 17.69% | 0.96% | |||
| SG&A Expenses | 6.07% | 10.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.52% | 7.82% | |||
| Operating Income | 7.27% | -11.26% | |||
| Income Before Tax | 11.33% | -15.90% | |||
| Income Tax Expenses | -18.53% | 1,858.06% | |||
| Earnings from Continuing Operations | 11.40% | -17.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.40% | -17.12% | |||
| EBIT | 7.27% | -11.26% | |||
| EBITDA | 7.31% | -11.37% | |||
| EPS Basic | 12.05% | -14.31% | |||
| Normalized Basic EPS | 12.14% | -14.05% | |||
| EPS Diluted | 12.05% | -14.31% | |||
| Normalized Diluted EPS | 12.14% | -14.05% | |||
| Average Basic Shares Outstanding | 0.91% | 1.64% | |||
| Average Diluted Shares Outstanding | 0.91% | 1.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||